Monash Lens
Professor Carl Kirkpatrick has helped edit a new collection of research papers largely focused on COVID-19 and what happens next. The start-point for society, and healthcare, he says, is that something similar will reoccur. He can even estimate when.
Carl Kirkpatrick
Professor, Centre for Medicine Use and Safety
“In eight to 10 years, there will very likely be another novel [new] virus,” says the Monash University pharmaceutical scientist. “We’ve had SARS-COV1 [SARS, 2003], H1N1 [Swine Flu, 2009], MERS-COV [Camel Flu, 2012], and now COVID-19. This current virus will change again, or it may be a different coronavirus, or another novel respiratory virus.”
Australia s current COVID-19 treatment options, and why the national fatility rate is so high
Posted Yesterday at 8:00pm
SatSaturday 3
updated 1
AprApril 2021 at 9:25am
Older people and people with compromised immune systems are more at risk of severe illness or death from COVID-19.
(
Share
Print text only
Cancel
As Australia s vaccine rollout eases slowly into its second phase, experts are pausing to reflect on how far we ve come with COVID-19 treatments and what the prospects are for saving more lives.
US-based Craig Rayner sits on the World Health Organization’s therapeutics committee for COVID-19. From a global view, we started off really with a mad dash to look for anything that we could re-purpose, said Dr Rayner, who is the president of integrated drug development at the company Certara.